Literature DB >> 12120257

Nucleic-acid therapeutics: basic principles and recent applications.

Joanna B Opalinska1, Alan M Gewirtz.   

Abstract

The sequencing of the human genome and the elucidation of many molecular pathways that are important in disease have provided unprecedented opportunities for the development of new therapeutics. The types of molecule in development are increasingly varied, and include antisense oligonucleotides and ribozymes. Antisense technology and catalytic nucleic-acid enzymes are important tools for blocking the expression of abnormal genes. One FDA-approved antisense drug is already in the clinic for the treatment of cytomegalovirus retinitis, and other nucleic-acid therapies are undergoing clinical trials. This article reviews different strategies for modulating gene expression, and discusses the successes and problems that are associated with this type of therapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12120257     DOI: 10.1038/nrd837

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  100 in total

1.  Site-directed recombination via bifunctional PNA-DNA conjugates.

Authors:  Faye A Rogers; Karen M Vasquez; Michael Egholm; Peter M Glazer
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-02       Impact factor: 11.205

2.  NMR solution structure of a parallel LNA quadruplex.

Authors:  Antonio Randazzo; Veronica Esposito; Oliver Ohlenschläger; Ramadurai Ramachandran; Luciano Mayola
Journal:  Nucleic Acids Res       Date:  2004-06-04       Impact factor: 16.971

3.  Novel monodisperse PEGtide dendrons: design, fabrication, and evaluation of mannose receptor-mediated macrophage targeting.

Authors:  Jieming Gao; Peiming Chen; Yashveer Singh; Xiaoping Zhang; Zoltan Szekely; Stanley Stein; Patrick J Sinko
Journal:  Bioconjug Chem       Date:  2013-08-21       Impact factor: 4.774

4.  Quantitative detection of siRNA and single-stranded oligonucleotides: relationship between uptake and biological activity of siRNA.

Authors:  Marita Overhoff; Winfried Wünsche; Georg Sczakiel
Journal:  Nucleic Acids Res       Date:  2004-12-02       Impact factor: 16.971

5.  Can Carrier-Mediated Delivery System Promote the Development of Antisense Imaging?

Authors:  Chang-bin Liu; Jun-qing Xu; Bai-xuan Xu; Jin-ming Zhang; Ying-mao Chen; Rui-min Wang; Jia-he Tian
Journal:  Mol Imaging Biol       Date:  2015-10       Impact factor: 3.488

6.  Nano-flares: probes for transfection and mRNA detection in living cells.

Authors:  Dwight S Seferos; David A Giljohann; Haley D Hill; Andrew E Prigodich; Chad A Mirkin
Journal:  J Am Chem Soc       Date:  2007-11-23       Impact factor: 15.419

Review 7.  Gene modulation for treating liver fibrosis.

Authors:  Kun Cheng; Ram I Mahato
Journal:  Crit Rev Ther Drug Carrier Syst       Date:  2007       Impact factor: 4.889

8.  Increased RNAi is related to intracellular release of siRNA via a covalently attached signal peptide.

Authors:  Anke Detzer; Marita Overhoff; Winfried Wünsche; Maria Rompf; John J Turner; Gabriela D Ivanova; Michael J Gait; Georg Sczakiel
Journal:  RNA       Date:  2009-02-18       Impact factor: 4.942

9.  A new potent secondary amphipathic cell-penetrating peptide for siRNA delivery into mammalian cells.

Authors:  Laurence Crombez; Gudrun Aldrian-Herrada; Karidia Konate; Quan N Nguyen; Gary K McMaster; Robert Brasseur; Frederic Heitz; Gilles Divita
Journal:  Mol Ther       Date:  2008-10-28       Impact factor: 11.454

Review 10.  Crystallographic studies of chemically modified nucleic acids: a backward glance.

Authors:  Martin Egli; Pradeep S Pallan
Journal:  Chem Biodivers       Date:  2010-01       Impact factor: 2.408

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.